DEVELOPMENT OF A NOVEL HUMAN SINGLE CHAIN ANTIBODY AGAINST EGFRVIII ANTIGEN BY PHAGE DISPLAY TECHNOLOGY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Rahbarnia Leila; FARAJNIA SAFAR; BABAEI HOSSEIN; MAJIDI JAFAR; AKBARI BAHMAN; AHDI KHOSROSHAHI SHIVA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Advanced Pharmaceutical Bulletin Year:2016 | Volume:6 | Issue:4 Page(s): 563-571

Download Full-Text

View:

231

Download:

133

Cites:

Information Journal Paper

Title

DEVELOPMENT OF A NOVEL HUMAN SINGLE CHAIN ANTIBODY AGAINST EGFRVIII ANTIGEN BY PHAGE DISPLAY TECHNOLOGY

Author(s)

Keywords

HUMAN SINGLE CHAIN ANTIBODY

CANCER

EGFRVIII

PHAGE DISPLAY

Abstract

Purpose: EGFRVIII as the most common mutant variant of the epidermal growth factor receptor is resulting from deletion of exons 2–7 in the coding sequence and junction of exons 1 and 8 through a novel glycine residue. EGFRVIII is highly expressed in glioblastoma, carcinoma of the breast, ovary, and lung but not in normal cells. The aim of the present study was identification of a novel single chain antibody against EGFRVIII as a promising target for CANCER therapy.Methods: In this study, a synthetic peptide corresponding to EGFRVIII protein was used for screening a naive human scFv phage library. A novel five-round selection strategy was used for enrichment of rare specific clones.Results: After five rounds of screening, six positive scFv clones against EGFRVIII were selected using monoclonal phage ELISA, among them, only three clones had expected size in PCR reaction. The specific interaction of two of the scFv clones with EGFRVIII was confirmed by indirect ELISA. One phage clone with higher affinity in scFv ELISA was purified for further analysis. The purity of the produced scFv antibody was confirmed using SDS-PAGE and Western blotting analyses.Conclusion: In the present study, a human anti- EGFRVIII scFv with high affinity was first identified from a scFv phage library. This study can be the groundwork for developing more effective diagnostic and therapeutic agents against EGFRVIII expressing CANCERs.

Cites

No record.

References

No record.

Cite

APA: Copy

Rahbarnia, Leila, FARAJNIA, SAFAR, BABAEI, HOSSEIN, MAJIDI, JAFAR, AKBARI, BAHMAN, & AHDI KHOSROSHAHI, SHIVA. (2016). DEVELOPMENT OF A NOVEL HUMAN SINGLE CHAIN ANTIBODY AGAINST EGFRVIII ANTIGEN BY PHAGE DISPLAY TECHNOLOGY. ADVANCED PHARMACEUTICAL BULLETIN, 6(4), 563-571. SID. https://sid.ir/paper/331838/en

Vancouver: Copy

Rahbarnia Leila, FARAJNIA SAFAR, BABAEI HOSSEIN, MAJIDI JAFAR, AKBARI BAHMAN, AHDI KHOSROSHAHI SHIVA. DEVELOPMENT OF A NOVEL HUMAN SINGLE CHAIN ANTIBODY AGAINST EGFRVIII ANTIGEN BY PHAGE DISPLAY TECHNOLOGY. ADVANCED PHARMACEUTICAL BULLETIN[Internet]. 2016;6(4):563-571. Available from: https://sid.ir/paper/331838/en

IEEE: Copy

Leila Rahbarnia, SAFAR FARAJNIA, HOSSEIN BABAEI, JAFAR MAJIDI, BAHMAN AKBARI, and SHIVA AHDI KHOSROSHAHI, “DEVELOPMENT OF A NOVEL HUMAN SINGLE CHAIN ANTIBODY AGAINST EGFRVIII ANTIGEN BY PHAGE DISPLAY TECHNOLOGY,” ADVANCED PHARMACEUTICAL BULLETIN, vol. 6, no. 4, pp. 563–571, 2016, [Online]. Available: https://sid.ir/paper/331838/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops